John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the

Levetiracetam: preliminary efficacy in generalized seizures Volume 5, supplément 1, Supplement, May 2003

Auteurs
Neurological Department, Medical Center Alkmaar, The Netherlands Clinique Neurologique, Strasbourg, France
  • Mots-clés : Levetiracetam, generalized seizures, myoclonic seizures, absence seizures
  • Page(s) : 39-44
  • Année de parution : 2003

Levetiracetam is a novel antiepileptic drug (AED) with proven efficacy against partial seizures, but there is limited information about its effectiveness against generalized seizures. In animal models, levetiracetam protects against seizures in audiogenic susceptible rodents, and it is effective in the Genetic Absence Epilepsy Rat from Strasbourg, a model of absence seizures. In these models, levetiracetam has a therapeutic index that is higher than those of other AEDs. A number of small open‐label studies suggest that levetiracetam reduces seizure frequency in patients with generalized seizures, including primarily generalized seizures and myoclonic seizures. Case reports provide additional information regarding the potential efficacy of levetiracetam in postanoxic, post‐encephalitic and progressive myoclonus. Although randomized controlled studies of patients with generalized seizures have not yet been conducted, on the basis of available information, levetiracetam may be promising in the treatment of generalized seizures.